USPH Historical Cash Flow
| USPH Stock | USD 74.00 0.95 1.27% |
Analysis of US Physicalrapy cash flow over time is an excellent tool to project US Physicalrapy future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 69 M or Other Non Cash Items of 5.7 M as it is a great indicator of US Physicalrapy ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining US Physicalrapy latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether US Physicalrapy is a good buy for the upcoming year.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. About USPH Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in USPH balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which USPH's non-liquid assets can be easily converted into cash.
US Physicalrapy Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by US Physicalrapy to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of US Physicalrapy operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from US Physicalrapy's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into US Physicalrapy current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.As of now, US Physicalrapy's End Period Cash Flow is increasing as compared to previous years. The US Physicalrapy's current Begin Period Cash Flow is estimated to increase to about 160.5 M, while Change In Cash is forecasted to increase to (105.9 M).
| 2022 | 2023 | 2024 | 2025 (projected) | Stock Based Compensation | 7.3M | 7.2M | 7.8M | 4.7M | Depreciation | 14.7M | 15.7M | 18.7M | 19.6M |
US Physicalrapy cash flow statement Correlations
Click cells to compare fundamentals
US Physicalrapy Account Relationship Matchups
High Positive Relationship
High Negative Relationship
US Physicalrapy cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 9.4M | (4.4M) | 3.0M | 121.2M | (111.5M) | (105.9M) | |
| Free Cash Flow | 92.4M | 68.2M | 50.3M | 72.7M | 65.8M | 69.0M | |
| Change In Working Capital | 23.6M | (11.7M) | (21.4M) | (4.9M) | (12.4M) | (11.8M) | |
| Total Cashflows From Investing Activities | (51.2M) | (124.1M) | (81.3M) | (45.0M) | (149.5M) | (142.0M) | |
| Other Cashflows From Financing Activities | 209.7M | 285.0M | 233.9M | (16.1M) | (14.7M) | (14.0M) | |
| Other Non Cash Items | 5.7M | 5.1M | 10.2M | 22.3M | 9.9M | 5.7M | |
| Capital Expenditures | 7.6M | 8.2M | 8.2M | 9.3M | 9.2M | 5.5M | |
| Total Cash From Operating Activities | 100.0M | 76.4M | 58.5M | 82.0M | 74.9M | 78.7M | |
| Net Income | 52.5M | 57.9M | 43.4M | 37.2M | 45.6M | 47.9M | |
| Total Cash From Financing Activities | (39.4M) | 43.4M | 25.8M | 84.3M | (37.0M) | (35.1M) | |
| End Period Cash Flow | 32.9M | 28.6M | 31.6M | 152.8M | 41.4M | 43.4M | |
| Other Cashflows From Investing Activities | (43.5M) | (114.7M) | 1.3M | 1.2M | (140.3M) | (133.3M) | |
| Begin Period Cash Flow | 23.5M | 32.9M | 28.6M | 31.6M | 152.8M | 160.5M | |
| Depreciation | 10.5M | 11.6M | 14.7M | 15.7M | 18.7M | 19.6M | |
| Stock Based Compensation | 7.9M | 7.9M | 7.3M | 7.2M | 7.8M | 4.7M | |
| Change To Liabilities | (5.2M) | 16.9M | 4.7M | (7.8M) | (8.9M) | (8.5M) | |
| Change To Inventory | (742K) | 4.2M | (12.4M) | (4.7M) | (5.4M) | (5.6M) | |
| Change To Account Receivables | 899K | (9.4M) | (10.3M) | (6.0M) | (5.3M) | (5.6M) | |
| Dividends Paid | 4.1M | 18.8M | 21.3M | 24.1M | 26.5M | 27.9M | |
| Investments | (111K) | 427K | (81.3M) | (80.0M) | (149.5M) | (142.0M) | |
| Change Receivables | (4.5M) | (8.9M) | 2.6M | (11.0M) | (9.9M) | (9.4M) | |
| Net Borrowings | 6.6M | (31.0M) | 93.1M | 64.2M | 73.8M | 77.5M | |
| Cash And Cash Equivalents Changes | 1.4M | 180K | 9.4M | (4.4M) | (5.0M) | (4.8M) | |
| Cash Flows Other Operating | 345K | (7.4M) | 3.1M | (633K) | (728.0K) | (691.6K) | |
| Change To Netincome | 16.6M | 14.4M | 35.7M | 33.1M | 38.0M | 39.9M | |
| Change To Operating Activities | (5.4M) | 10.3M | (7.0M) | (3.4M) | (3.1M) | (2.9M) |
Currently Active Assets on Macroaxis
When determining whether US Physicalrapy offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of US Physicalrapy's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Us Physicalrapy Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Us Physicalrapy Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.716 | Dividend Share 1.77 | Earnings Share 2.18 | Revenue Per Share | Quarterly Revenue Growth 0.181 |
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.